Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Purchases $108,752.21 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero acquired 78,239 shares of the business’s stock in a transaction that occurred on Thursday, August 27th. The shares were acquired at an average cost of $1.39 per share, for a total transaction of $108,752.21. Following the transaction, the director owned 689,081 shares of the company’s stock, valued at approximately $957,822.59. This represents a 12.81% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Ramiro Guerrero also recently made the following trade(s):

• On Friday, August 28th, Ramiro Guerrero bought 46,620 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.35 per share, with a total value of $62,937.00.
• On Wednesday, August 26th, Ramiro Guerrero bought 8,931 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.39 per share, with a total value of $12,414.09.
• On Monday, August 24th, Ramiro Guerrero bought 1,794 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $1.33 per share, with a total value of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero purchased 11,899 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.37 per share, for a total transaction of $16,301.63.

MAIA Biotechnology Stock Down 0.8%

Shares of MAIA traded down $0.01 during mid-day trading on Tuesday, hitting $1.30. 304,095 shares of the company’s stock were exchanged, compared to its average volume of 791,682. The stock has a market cap of $79.08 million, a price-to-earnings ratio of -2.10 and a beta of 0.24. The firm has a fifty day moving average of $1.37 and a two-hundred day moving average of $1.44. MAIA Biotechnology, Inc. has a twelve month low of $0.87 and a twelve month high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities analysts predict that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current year.

Institutional Trading of MAIA Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP bought a new stake in shares of MAIA Biotechnology during the 2nd quarter worth about $29,000. PVG Asset Management Corp bought a new position in shares of MAIA Biotechnology in the 1st quarter valued at approximately $46,000. Susquehanna International Group LLP bought a new position in shares of MAIA Biotechnology in the 2nd quarter valued at approximately $51,000. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology in the 2nd quarter valued at approximately $52,000. Finally, Corsair Capital Management L.P. acquired a new stake in MAIA Biotechnology in the 1st quarter worth approximately $140,000. Institutional investors and hedge funds own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.